A5048471522- Inflammatory Bowel Disease
- Microscopic Colitis
- Biosimilars and Bioanalytical Methods
- Autoimmune and Inflammatory Disorders Research
- Diagnosis and treatment of tuberculosis
- Pharmaceutical studies and practices
- Liver Diseases and Immunity
- Liver physiology and pathology
- Inflammasome and immune disorders
- Celiac Disease Research and Management
- Pharmaceutical Practices and Patient Outcomes
- Tuberculosis Research and Epidemiology
- Pharmacological Effects of Natural Compounds
- Patient Safety and Medication Errors
- Pharmaceutical Economics and Policy
- Innovations in Medical Education
- Cytokine Signaling Pathways and Interactions
- Eosinophilic Esophagitis
- Immunodeficiency and Autoimmune Disorders
Austin Health
2020-2025
Austin Hospital
2023-2024
The University of Melbourne
2023-2024
Melbourne Health
2023
Preliminary data regarding the effectiveness of tofacitinib in acute severe ulcerative colitis [ASUC] have been presented two previous case series. We aimed to describe novel use high-dose immediately following non-response infliximab setting steroid-refractory ASUC.Five patients who received 10 mg three times a day for ASUC were identified at an Australian tertiary inflammatory bowel disease centre.Four five demonstrated clinical response induction during their inpatient admission, with one...
Abstract Background Although the ‘gut-specific’ safety profile of vedolizumab may be considered advantageous in inflammatory bowel disease (IBD) patients on concomitant immunosuppression following liver transplant, has not been compared with ‘systemic’ biologic therapies this context. This study aimed to compare and manage IBD transplantation (LTx). Methods A retrospective observational exposed therapy LTx was undertaken across two Australian centers. The primary outcome incidence rate...
Abstract Acute severe colitis (ASUC) remains a significant cause of morbidity in up to 25% patients with ulcerative during their disease course. We present the outcomes out 12 months following use high‐dose tofacitinib, 10 mg three times daily (TDS), steroid and infliximab refractory ASUC. A total 11 ASUC who were treated tofacitinib after failing sequential therapy between 2019 2021 identified at an Australian tertiary centre. Ten demonstrated clinical biochemical response treatment...
Abstract Background Biologic drugs are highly effective for inflammatory bowel disease (IBD) management but key drivers of costs care especially when administered intravenously (i.v.). Availability subcutaneous (SC) formulations has increased convenience patients and improved access to care, at the cost revenue health services. Aims To evaluate economic impact transitioning a tertiary centre IBD cohort from i.v. SC biologic administration assess implications stakeholders. Methods A...
The management of inflammatory bowel disease [IBD] patients with concurrent liver transplantation is challenging, and data regarding the safety efficacy Janus kinase [JAK] inhibitors anti-rejection medications are required. We report experience all transplant recipients receiving tofacitinib and/or upadacitinib for IBD across three states in Australia.
A substantial proportion of patients with inflammatory bowel disease (IBD) on intravenous infliximab require dose intensification. Accessing additional is labour-intensive and expensive, depending insurance pharmaceutical reimbursement. Observational data suggest that subcutaneous may offer a convenient safe alternative to maintain remission in requiring dose-intensified infliximab. prospective, controlled trial required confirm as effective infliximab, identify predictors flare establish...
Abstract Recent data, indicating that inflammatory bowel disease (IBD) may be a risk factor for future chronic kidney disease, highlight the need to study safety and clinical effectiveness of advanced IBD therapies in patients with end stage renal (ESRD), defined as an eGFR <15 mL/min/1.73m 2 . Upadacitinib, selective oral Janus kinase (JAK) 1 inhibitor, has demonstrated efficacy management moderate severe ulcerative colitis. There is also emerging data JAK inhibition clinically effective...
The World Health Organization has recommended that the management of chronic diseases such as inflammatory bowel disease (IBD) should be undertaken using an integrated approach delivered by a multidisciplinary team. Although composition IBD team been well described, inclusion pharmacist core member more recent, with variable uptake within services internationally. While pharmacists continue to play traditional role safe prescribing and monitoring immunosuppressive therapies, their is rapidly...
Abstract Background Despite evidence to support pharmacists practicing in advanced scope roles, embedding such roles into practice is challenging. Upskilling hospital pharmacy technicians (HPTs) undertake selected clinical under indirect supervision could relieve from non‐complex tasks. Aim To compare patient satisfaction with routine postoperative discharge medication education provided by a HPT or short‐stay surgery setting. Method An completed comprehensive training program become...
Abstract Background Biologic drugs are highly effective for inflammatory bowel disease (IBD) management but key drivers of costs care especially when administered intravenously (IV). Availability subcutaneous (SC) formulations has increased convenience patients and improved access to at the cost revenue health services. The aim this study was evaluate economic impact transitioning a tertiary centre IBD cohort from IV SC biologic administration assess implications stakeholders. Methods A...
Abstract Background Acute Severe Ulcerative Colitis (ASUC) remains a significant cause of morbidity faced by up to 25% patients with ulcerative colitis at some point during their disease course. We present the outcomes 1 year after novel use high dose tofacitinib, in steroid refractory ASUC failing respond infliximab. Methods Eleven who were treated sequential tofacitinib [10mg three times daily (TDS)] infliximab between 2019-2021 identified an Australian tertiary centre. Results Nine 11...
Abstract Background Vedolizumab is effective in inducing and maintaining remission patients with both Crohn’s Disease (CD) ulcerative colitis (UC). Recent data has demonstrated that there superior persistence vedolizumab compared to anti-TNF biologics. However, the efficacy of dose intensified remains uncertain. We aimed assess whether intensification resulted a meaningful improvement treatment determine were any clinical, biochemical or endoscopic parameters associated response...
Abstract Background The availability of subcutaneous (SC) administration devices biologics in addition to intravenous (IV) has influenced patients’ and clinicians’ preferences towards initiating or transitioning SC particularly during the COVID-19 pandemic. Whilst improves patient convenience reduces demands on infusion centres we hypothesised that reduction healthcare contact associated with therapies may reduce opportunities available for objective disease assessment. We aimed compare...